Prior close: $3.67
A great start to the year
Healius (ASX:HLS) provided a strong first quarter update last week, confirming our positive view on the stock. COVID-19 testing generated particularly strong revenue and earnings growth in the company’s pathology operations, and its day hospitals are also performing strongly. Is there more upside in this healthcare group which has been a strong outperformer in recent months?